JP2008524246A - ヒストンデアセチラーゼ阻害剤 - Google Patents

ヒストンデアセチラーゼ阻害剤 Download PDF

Info

Publication number
JP2008524246A
JP2008524246A JP2007546970A JP2007546970A JP2008524246A JP 2008524246 A JP2008524246 A JP 2008524246A JP 2007546970 A JP2007546970 A JP 2007546970A JP 2007546970 A JP2007546970 A JP 2007546970A JP 2008524246 A JP2008524246 A JP 2008524246A
Authority
JP
Japan
Prior art keywords
alkyl
cycloalkyl
hetero
bicycloaryl
methyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2007546970A
Other languages
English (en)
Japanese (ja)
Other versions
JP2008524246A5 (https=
Inventor
ブレッシ、ジェローム、シー．
ブラウン、ジェイソン、ダヴリュ．
ガングロフ、アンソニー、アール．
ジェニングス、アンドリュー、ジェイ．
カルドール、スティーヴン、ダヴリュ．
スキーン、ロバート、ジェイ．
スタフォード、ジェフェリー、エイ．
ヴー、フォン、エイチ．
Original Assignee
タケダ サン ディエゴ インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by タケダ サン ディエゴ インコーポレイテッド filed Critical タケダ サン ディエゴ インコーポレイテッド
Publication of JP2008524246A publication Critical patent/JP2008524246A/ja
Publication of JP2008524246A5 publication Critical patent/JP2008524246A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D235/26—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D263/34—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D263/36—One oxygen atom
    • C07D263/38—One oxygen atom attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
    • C07D263/54—Benzoxazoles; Hydrogenated benzoxazoles
    • C07D263/58—Benzoxazoles; Hydrogenated benzoxazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D277/62—Benzothiazoles
    • C07D277/68—Benzothiazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D277/62—Benzothiazoles
    • C07D277/68—Benzothiazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D277/70—Sulfur atoms
    • C07D277/72—2-Mercaptobenzothiazole
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
JP2007546970A 2004-12-16 2005-12-16 ヒストンデアセチラーゼ阻害剤 Pending JP2008524246A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US63697404P 2004-12-16 2004-12-16
PCT/US2005/045779 WO2006066133A2 (en) 2004-12-16 2005-12-16 Histone deacetylase inhibitors

Publications (2)

Publication Number Publication Date
JP2008524246A true JP2008524246A (ja) 2008-07-10
JP2008524246A5 JP2008524246A5 (https=) 2009-02-12

Family

ID=36588612

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2007546970A Pending JP2008524246A (ja) 2004-12-16 2005-12-16 ヒストンデアセチラーゼ阻害剤

Country Status (4)

Country Link
US (1) US7642275B2 (https=)
EP (1) EP1824831A2 (https=)
JP (1) JP2008524246A (https=)
WO (1) WO2006066133A2 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5484069B2 (ja) * 2007-12-19 2014-05-07 大日本住友製薬株式会社 二環性へテロ環誘導体

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008524246A (ja) 2004-12-16 2008-07-10 タケダ サン ディエゴ インコーポレイテッド ヒストンデアセチラーゼ阻害剤
US7642253B2 (en) 2005-05-11 2010-01-05 Takeda San Diego, Inc. Histone deacetylase inhibitors
BRPI0613430A2 (pt) 2005-07-13 2011-01-11 Hoffmann La Roche compostos derivados de benzimidazol, uso dos mesmos, método para a preparação destes e composição farmacêutica
WO2007015877A2 (en) * 2005-07-20 2007-02-08 Kalypsys, Inc. Inhibitors of p38 kinase and methods of treating inflammatory disorders
DE102006024024A1 (de) 2006-05-23 2007-11-29 Bayer Healthcare Aktiengesellschaft Substituierte Arylimidazolone und -triazolone sowie ihre Verwendung
US7961810B2 (en) * 2006-09-07 2011-06-14 Texas Instruments Incorporated Antenna grouping and group-based enhancements for MIMO systems
WO2008089436A2 (en) * 2007-01-18 2008-07-24 Takeda San Diego, Inc. Crystalline forms of histone deacetylase inhibitors
US8030344B2 (en) * 2007-03-13 2011-10-04 Methylgene Inc. Inhibitors of histone deacetylase
EP3103791B1 (en) * 2007-06-27 2018-01-31 Merck Sharp & Dohme Corp. 4-carboxybenzylamino derivatives as histone deacetylase inhibitors
EP2231596A4 (en) * 2007-12-14 2012-06-06 Univ Georgetown INHIBITORS OF HISTONATE ACETYLASE
EP2242367A4 (en) * 2008-01-08 2012-07-04 Univ Pennsylvania Rel inhibitors and methods of use thereof
AR070220A1 (es) * 2008-01-22 2010-03-25 Boehringer Ingelheim Int Amino-bencimidazoles sustituidos medicamentos que comprenden dicho compuestos, uso y metodos de fabricacion de los mismos
DE102008022221A1 (de) * 2008-05-06 2009-11-12 Universität des Saarlandes Inhibitoren der humanen Aldosteronsynthase CYP11B2
US9643922B2 (en) * 2008-08-18 2017-05-09 Yale University MIF modulators
US9540322B2 (en) 2008-08-18 2017-01-10 Yale University MIF modulators
WO2010025375A1 (en) 2008-08-29 2010-03-04 Treventis Corporation Compositions and methods of treating amyloid disease
EP2330894B8 (en) 2008-09-03 2017-04-19 BioMarin Pharmaceutical Inc. Compositions including 6-aminohexanoic acid derivatives as hdac inhibitors
DE102008060967A1 (de) 2008-12-06 2010-06-10 Bayer Schering Pharma Aktiengesellschaft Substituierte Phenylsulfonyltriazolone und ihre Verwendung
DE102009003975A1 (de) * 2009-01-07 2010-07-08 Merck Patent Gmbh Benzothiazolonderivate
DE102010001064A1 (de) 2009-03-18 2010-09-23 Bayer Schering Pharma Aktiengesellschaft Substituierte 2-Acetamido-5-Aryl-1,2,4-triazolone und deren Verwendung
EP2430011A1 (en) 2009-05-15 2012-03-21 Novartis AG 5-pyridin-3-yl-1,3-dihydro-indol-2-on derivatives and their use as modulators of aldosterone synthase and/or cyp11b1
WO2010130773A2 (en) 2009-05-15 2010-11-18 Novartis Ag Benzoxazolone derivatives as aldosterone symthase inhibitors
AU2010263113B2 (en) * 2009-06-23 2015-11-26 Translational Drug Development, Llc Benzamide derivatives
KR20120109292A (ko) 2009-06-24 2012-10-08 다이닛본 스미토모 세이야꾸 가부시끼가이샤 Ｎ-치환-시클릭 아미노 유도체
WO2011042145A1 (en) * 2009-10-07 2011-04-14 Siena Biotech S.P.A. Wnt pathway antagonists
EA023221B1 (ru) 2010-02-27 2016-05-31 Байер Интеллектуэль Проперти Гмбх СВЯЗАННЫЕ БИС-АРИЛЬНЫЕ АРИЛ-ТРИАЗОЛОНЫ, СПОСОБЫ ИХ ПОЛУЧЕНИЯ, ИХ ПРИМЕНЕНИЕ, ЛЕКАРСТВЕННОЕ СРЕДСТВО НА ИХ ОСНОВЕ И ДВОЙНОЙ АНТАГОНИСТ V1a/V2-РЕЦЕПТОРОВ
EP2366398A1 (en) * 2010-03-17 2011-09-21 Deutsches Krebsforschungszentrum Cancer therapy with a parvovirus combined with an HDAC inhibitor
DE102010040187A1 (de) 2010-09-02 2012-03-08 Bayer Schering Pharma Aktiengesellschaft Substituierte N-Phenethyl-triazolonacetamide und ihre Verwendung
DE102010040924A1 (de) 2010-09-16 2012-03-22 Bayer Schering Pharma Aktiengesellschaft Substituierte Phenylacet- und Phenylpropanamide und ihre Verwendung
US9540395B2 (en) 2011-02-28 2017-01-10 Biomarin Pharmaceutical Inc. Histone deacetylase inhibitors
US8957066B2 (en) 2011-02-28 2015-02-17 Biomarin Pharmaceutical Inc. Histone deacetylase inhibitors
US10059723B2 (en) 2011-02-28 2018-08-28 Biomarin Pharmaceutical Inc. Histone deacetylase inhibitors
EP2723338A2 (en) * 2011-06-24 2014-04-30 The Trustees of Stevens Institute of Technology Selective inhibitors of histone deacetylase isoform 6 and methods thereof
WO2014143666A1 (en) 2013-03-15 2014-09-18 Biomarin Pharmaceutical Inc. Hdac inhibitors
UA121558C2 (uk) 2014-11-03 2020-06-25 Баєр Фарма Актіенгезеллшафт Гідроксіалкілзаміщені фенілтриазольні похідні та їх застосування
EP3223816B1 (en) 2014-11-26 2020-04-22 The J. David Gladstone Institutes Methods for treating a cytomegalovirus infection
US9988367B2 (en) 2016-05-03 2018-06-05 Bayer Pharma Aktiengesellschaft Amide-substituted pyridinyltriazole derivatives and uses thereof
WO2018165520A1 (en) 2017-03-10 2018-09-13 Vps-3, Inc. Metalloenzyme inhibitor compounds
CN107954988A (zh) * 2017-12-22 2018-04-24 田立志 一种磺酰胺衍生物、制备方法及其作为nampt抑制剂在抗肿瘤药物中的应用
CN107987060A (zh) * 2017-12-22 2018-05-04 田立志 一种磺酰胺衍生物及其作为nampt抑制剂在抗肿瘤药物中的应用
CN108042538A (zh) * 2017-12-22 2018-05-18 田立志 一种磺酰胺衍生物及其作为nampt抑制剂的应用
CN107915721A (zh) * 2017-12-22 2018-04-17 田立志 一种磺酰胺衍生物及其作为烟酰胺磷酸核糖转移酶抑制剂在抗肿瘤药物中的应用
CN107903246A (zh) * 2017-12-22 2018-04-13 田立志 一种磺酰胺衍生物、制备方法及其抗肿瘤中的应用
CN108042539A (zh) * 2017-12-22 2018-05-18 田立志 一种磺酰胺衍生物、制备方法及其在抗肿瘤药物中的应用
CN107954987A (zh) * 2017-12-22 2018-04-24 田立志 一种磺酰胺衍生物及其在抗肿瘤药物中的应用
US12606829B2 (en) 2018-06-12 2026-04-21 The J. David Gladstone Institutes, A Testamentary Trust Established Under The Will Of J. David Gladstone Compositions for herpesvirus transcriptional feedback circuit disruption and uses thereof
WO2020186101A1 (en) 2019-03-12 2020-09-17 The Broad Institute, Inc. Detection means, compositions and methods for modulating synovial sarcoma cells
AU2020321955A1 (en) 2019-07-30 2022-03-17 Eikonizo Therapapeutics, Inc. HDAC6 inhibitors and uses thereof
IL316201A (en) 2022-04-08 2024-12-01 Eikonizo Therapeutics Inc Oxadiazole HDAC6 inhibitors and their uses

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH10152462A (ja) * 1996-09-30 1998-06-09 Mitsui Chem Inc 分化誘導剤
WO2003092686A1 (en) * 2002-04-27 2003-11-13 Astrazeneca Ab Inhibitors of histone deacetylase
WO2004052838A1 (en) * 2002-12-10 2004-06-24 F. Hoffmann-La Roche Ag Arylene-carboxylic acid (2-amino-phenyl)-amide derivatives as pharmaceutical agents
WO2004058234A2 (en) * 2002-12-27 2004-07-15 Schering Aktiengesellschaft Pharmaceutical combinations of phthalazine vegf inhibitors and benzamide hdac inhibitors
WO2004069803A2 (en) * 2003-02-06 2004-08-19 F. Hoffmann-La Roche Ag Mono-acylated o-phenylendiamines derivatives and their use against cancer

Family Cites Families (322)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4482571A (en) 1982-06-21 1984-11-13 University Of Pittsburgh Sickle cell anemia treatment and compound
GB8524157D0 (en) 1984-10-19 1985-11-06 Ici America Inc Heterocyclic amides
GB8607294D0 (en) 1985-04-17 1986-04-30 Ici America Inc Heterocyclic amide derivatives
DK496086A (da) 1985-10-17 1987-04-18 Ici America Inc Heterocykliske forbindelser
US4964895A (en) 1987-06-08 1990-10-23 Monsanto Company Substituted 4-(4-nitrophenoxy) pyrazoles and their use as herbicides
US4997815A (en) * 1988-11-01 1991-03-05 Children's Hospital Medical Center Of Northern California Method for augmenting fetal hemoglobin by treatment with activin and/or inhibin
CA2046628A1 (en) 1989-02-08 1990-08-09 Dee W. Brooks 4-hydroxythiazoles as 5-lipoxygenase inhibitors
US5216004A (en) 1990-09-13 1993-06-01 Children's Hospital Medical Center Of North California Method for preventing malaria
US5656644A (en) 1994-07-20 1997-08-12 Smithkline Beecham Corporation Pyridyl imidazoles
US5439939A (en) 1992-03-17 1995-08-08 Children's Hospital Medical Center Of Northern California Pharmaceutical compositions and methods using isobutyramide for treating betaglobin disorders
WO1995011699A1 (en) * 1993-10-29 1995-05-04 The Trustees Of Boston University Physiologically stable compositions of butyric acid, and butyric acid salts and derivatives as anti-neoplastic agents
EP0727989A4 (en) 1993-11-10 1998-08-19 Sloan Kettering Inst Cancer BUTTERIC ACID ESTERS AS CELL DIFFERENTIATING ACTIVE SUBSTANCES
US5569675A (en) 1994-03-07 1996-10-29 Bar Ilan University Methods of using carboxylic acid esters to increase fetal-hemoglobin levels
AU702943B2 (en) * 1994-04-13 1999-03-11 Beckman Instruments, Inc. Analysis of analytes in biological fluids
US6071923A (en) 1994-09-16 2000-06-06 Bar-Ilan University Retinoyloxy aryl-substituted alkylene butyrates useful for the treatment of cancer and other proliferative diseases
US6040342A (en) * 1994-09-16 2000-03-21 Bar-Ilan University Retinoyloxy (alkyl-substituted) methyl butyrates useful for the treatment of cancer and other proliferative diseases
US5789434A (en) 1994-11-15 1998-08-04 Bayer Corporation Derivatives of substituted 4-biarylbutyric acid as matrix metalloprotease inhibitors
US6011000A (en) * 1995-03-03 2000-01-04 Perrine; Susan P. Compositions for the treatment of blood disorders
US5700826A (en) 1995-06-07 1997-12-23 Ontogen Corporation 1,2,4,5-tetra substituted imidazoles as modulators of multi-drug resistance
JP3964478B2 (ja) 1995-06-30 2007-08-22 エーザイ・アール・アンド・ディー・マネジメント株式会社 ヘテロ環含有カルボン酸誘導体及びそれを含有する医薬
US5922837A (en) 1995-09-20 1999-07-13 Merck & Co., Inc. Antiprotozoal cyclic tetrapeptides
US6110697A (en) 1995-09-20 2000-08-29 Merck & Co., Inc. Histone deacetylase as target for antiprotozoal agents
WO1997011366A1 (en) 1995-09-20 1997-03-27 Merck & Co., Inc. Histone deacetylase as target for antiprotozoal agents
US20030219832A1 (en) 1996-03-11 2003-11-27 Klein Elliott S. Synthesis and use of retinoid compounds having negative hormone and/or antagonist activities
US6777217B1 (en) 1996-03-26 2004-08-17 President And Fellows Of Harvard College Histone deacetylases, and uses related thereto
WO1997047307A1 (en) 1996-06-14 1997-12-18 The Uab Research Foundation Use of histone deacetylase inhibitors to activate transgene expression
AU3588097A (en) 1996-07-02 1998-01-21 Bar-Ilan University Retinoyloxy(substituted)alkylene butyrates useful for the treatment of cancer and other proliferative diseases
US5939456A (en) 1996-07-26 1999-08-17 Perrine; Susan P. Pulsed administration of compositions for the treatment of blood disorders
US6197743B1 (en) 1996-07-26 2001-03-06 The Trustees Of Boston University Compositions and methods for the treatment of viral disorders
EP0827742A1 (en) 1996-09-04 1998-03-11 Vrije Universiteit Brussel Use of histone deacetylase inhibitors for treating fribosis or cirrhosis
US6068987A (en) * 1996-09-20 2000-05-30 Merck & Co., Inc. Histone deacetylase as target for antiprotozoal agents
US6794392B1 (en) * 1996-09-30 2004-09-21 Schering Aktiengesellschaft Cell differentiation inducer
US6174905B1 (en) * 1996-09-30 2001-01-16 Mitsui Chemicals, Inc. Cell differentiation inducer
CN1246847A (zh) 1996-12-23 2000-03-08 杜邦药品公司 作为Xa因子抑制剂的含氮杂芳族化合物
US6235474B1 (en) * 1996-12-30 2001-05-22 The Johns Hopkins University Methods and kits for diagnosing and determination of the predisposition for diseases
US6130248A (en) 1996-12-30 2000-10-10 Bar-Ilan University Tricarboxylic acid-containing oxyalkyl esters and uses thereof
WO1998029114A1 (en) 1996-12-30 1998-07-09 Bar-Ilan University Tricarboxylic acid-containing oxyalkyl esters and uses thereof
US7062219B2 (en) 1997-01-31 2006-06-13 Odyssey Thera Inc. Protein fragment complementation assays for high-throughput and high-content screening
US6124495A (en) 1997-03-11 2000-09-26 Beacon Laboratories, Inc. Unsaturated oxyalkylene esters and uses thereof
US5939455A (en) 1997-03-11 1999-08-17 Beacon Laboratories, Inc. Therapeutic augmentation of oxyalkylene diesters and butyric acid derivatives
US6110970A (en) 1997-03-11 2000-08-29 Beacon Laboratories, Inc. Nitrogen-containing oxyalkylene esters and uses thereof
US6043389A (en) * 1997-03-11 2000-03-28 Mor Research Applications, Ltd. Hydroxy and ether-containing oxyalkylene esters and uses thereof
US6110955A (en) 1997-03-11 2000-08-29 Beacon Laboratories, Inc. Metabolically stabilized oxyalkylene esters and uses thereof
US6030961A (en) * 1997-03-11 2000-02-29 Bar-Ilan Research & Development Co., Ltd. Oxyalkylene phosphate compounds and uses thereof
US6387673B1 (en) * 1997-05-01 2002-05-14 The Salk Institute For Biological Studies Compounds useful for the modulation of processes mediated by nuclear hormone receptors, methods for the identification and use of such compounds
US6231880B1 (en) * 1997-05-30 2001-05-15 Susan P. Perrine Compositions and administration of compositions for the treatment of blood disorders
AUPO721997A0 (en) 1997-06-06 1997-07-03 Queensland Institute Of Medical Research, The Anticancer compounds
AUPO864097A0 (en) 1997-08-19 1997-09-11 Peplin Pty Ltd Anti-cancer compounds
NZ503061A (en) 1997-09-02 2001-08-31 Japan Energy Corp Cyclic tetrapeptide derivatives and use as anti-cancer agents
EP1037533A1 (en) 1997-11-10 2000-09-27 The Salk Institute for Biological Studies Methods for the use of inhibitors of co-repressors for the treatment of neoplastic diseases
US6884597B1 (en) * 1998-01-20 2005-04-26 Medical & Biological Laboratories, Co., Ltd. Method for detecting acetyltransferase and deacetylase activities and method for screening inhibitors or enhancers of these enzymes
US6262116B1 (en) 1998-01-23 2001-07-17 Sloan-Kettering Institute For Cancer Research Transcription therapy for cancers
AU774861B2 (en) 1998-02-11 2004-07-08 Douglas V Faller Compositions and methods for the treatment of cystic fibrosis
US6287843B1 (en) 1998-04-03 2001-09-11 Pioneer Hi-Bred International, Inc. Maize histone deacetylases and their use
US6288063B1 (en) 1998-05-27 2001-09-11 Bayer Corporation Substituted 4-biarylbutyric and 5-biarylpentanoic acid derivatives as matrix metalloprotease inhibitors
US20030236204A1 (en) * 2002-06-14 2003-12-25 Isis Pharmaceuticals Inc. Antisense modulation of histone deacetylase 2 expression
AUPP505798A0 (en) 1998-08-04 1998-08-27 Fujisawa Pharmaceutical Co., Ltd. Novel compound fr225497 substance
EP1105143A4 (en) 1998-08-21 2002-07-17 Smithkline Beecham Corp HUMAN GENE OF HISTONE DEACETYLASE HD4
BR9914779A (pt) 1998-10-13 2001-07-03 Fujisawa Pharmaceutical Co Composto wf27082, processo para sua produção, composição farmacêutica contendo o mesmo, cepa de fundos pertencente ao gênero acremonium, composto tendo atividade inibidora de desacetilase de histona, processo para sua produção, seu método e uso
CA2346152A1 (en) 1998-10-16 2000-04-27 Novartis Ag Promotion of self-renewal and improved gene transduction of hematopoietic stem cells by histone deacetylase inhibitors
WO2000028020A2 (en) * 1998-11-10 2000-05-18 Board Of Regents, The University Of Texas System Methods for preventing cardiac hypertrophy and heart failure by inhibition of mef2 transcription factor
US6287790B1 (en) 1998-11-30 2001-09-11 The Regents Of The University Of California Utilization of nuclear structural proteins for targeted therapy and detection of proliferative and differentiation disorders
US6335170B1 (en) * 1999-02-22 2002-01-01 Torben F. Orntoft Gene expression in bladder tumors
JP4269041B2 (ja) 1999-03-02 2009-05-27 国立大学法人九州工業大学 新規な環状テトラペプチド誘導体とその医薬用途
ATE329058T1 (de) 1999-03-23 2006-06-15 Chugai Pharmaceutical Co Ltd Verfahren zum screenen nach gegen krebs gerichteten medikamenten
US6518012B1 (en) * 1999-04-02 2003-02-11 Health Research, Inc. Method for regulating the expression of MHC antigens and CD40 by inhibitors of histone deacetylation
DE60001229T2 (de) 1999-04-09 2003-10-30 Smithkline Beecham Corp., Philadelphia Triarylimidazole
US20030078216A1 (en) * 1999-05-03 2003-04-24 Macleod A. Robert Inhibition of histone deactylase
JP2003500052A (ja) 1999-05-03 2003-01-07 メチルジーン インコーポレイテッド ヒストン脱アセチル酵素の抑制
US20030078369A1 (en) * 1999-07-23 2003-04-24 Meinke Peter T. Apicidin-derived cyclic tetrapeptides
CA2378849A1 (en) 1999-07-23 2001-02-01 Merck & Co., Inc. Apicidin-derived cyclic tetrapeptides
JP2003507076A (ja) 1999-08-20 2003-02-25 ボード オブ リージェンツ， ザ ユニバーシティ オブ テキサス システム 心臓の遺伝子発現の調節におけるｈｄａｃ４およびｈｄａｃ５
JP2001081031A (ja) 1999-08-30 2001-03-27 Schering Ag 溶解性および経口吸収性を改善したベンズアミド誘導体含有製剤
AU7108400A (en) 1999-09-03 2001-04-10 Salk Institute For Biological Studies, The Modulation of gene expression by modulating histone acetylation
ATE361316T1 (de) 1999-09-08 2007-05-15 Sloan Kettering Inst Cancer Kristallstruktur einer deacetylase und deren inhibitoren
EA200601252A1 (ru) 1999-09-08 2006-10-27 Слоан-Кеттеринг Инститьют Фор Кэнсер Рисёч Новый класс веществ, вызывающих дифференцировку клеток и являющихся ингибиторами гистондеацетилазы, и способы их применения
AU7992600A (en) 1999-10-08 2001-04-23 Merck & Co., Inc. Antiprotozoal histone acetyl transferase inhibitors
KR20020070285A (ko) * 1999-11-23 2002-09-05 메틸진, 인크. 히스톤 디아세틸라제의 억제제
JP2001149081A (ja) * 1999-11-29 2001-06-05 Cyclex Co Ltd 脱アセチル化酵素の活性測定方法、並びにこれら酵素の阻害剤もしくは促進剤のスクリーニング方法
CA2291367A1 (en) 1999-12-06 2001-06-06 Isabelle Henry Genetic constructions having a reduced or an increased number of epigenetic control regions and methods of use thereof
EP1779859B1 (en) * 1999-12-08 2010-06-09 Cyclacel Pharmaceuticals, Inc. Use of depsipeptide and congeners thereof as immunosuppressants in preventing or treating rejection following transplantation and for induction of apoptosis of activated CD4 or CD8 T-cells
US6875598B1 (en) * 1999-12-08 2005-04-05 Applera Corporation Histone deacetylase-8 proteins, nuclei acids, and methods for use
US6828302B1 (en) 1999-12-08 2004-12-07 Xcyte Therapies, Inc. Therapeutic uses of depsipeptides and congeners thereof
AU1959001A (en) 1999-12-08 2001-06-18 Axys Pharmaceuticals, Inc. Histone deacetylase-8 proteins, nucleic acids, and methods of use
US7452664B2 (en) 1999-12-15 2008-11-18 Massachusetts Institute Of Technology Methods for identifying agents which alter histone protein acetylation
US6544957B2 (en) * 2000-01-04 2003-04-08 The Johns Hopkins University Methods and reagents for facilitating transcription
KR20020086508A (ko) * 2000-02-08 2002-11-18 상가모 바이오사이언스 인코포레이티드 약물 발견용 세포
AU2001250783A1 (en) 2000-02-29 2001-09-12 Cor Therapeutics, Inc. Benzamides and related inhibitors of factor xa
US20030129724A1 (en) 2000-03-03 2003-07-10 Grozinger Christina M. Class II human histone deacetylases, and uses related thereto
GB0005199D0 (en) 2000-03-04 2000-04-26 Imp College Innovations Ltd Modulation of histone deacetylase
GB0007217D0 (en) 2000-03-24 2000-05-17 Europ I Of Oncology Materials and methods relating to the treatment of leukaemias
EP2093292A2 (en) * 2000-03-24 2009-08-26 Methylgene, Inc. Inhibition of specific histone deacetylase isoforms
EP1268534A2 (en) 2000-03-24 2003-01-02 Filgen Biosciences, Inc. Peptides binding to non-acetylated h3 and h4 histones for cancer therapy
WO2002008273A2 (en) 2000-07-21 2002-01-31 Millennium Pharmaceuticals, Inc. 47508, a novel human histone deacetylase family member and uses thereof
US20020137162A1 (en) 2000-03-24 2002-09-26 Zuomei Li Antisense oligonucleotide inhibition of specific histone deacetylase isoforms
AU2001248701A1 (en) 2000-03-24 2001-10-03 Methylgene, Inc. Inhibitors of histone deacetylase
GB0007405D0 (en) 2000-03-27 2000-05-17 Smithkline Beecham Corp Compounds
US6458589B1 (en) * 2000-04-27 2002-10-01 Geron Corporation Hepatocyte lineage cells derived from pluripotent stem cells
EP1170008A1 (en) 2000-07-07 2002-01-09 Chemotherapeutisches Forschungsinstitut Georg-Speyer-Haus Valproic acid and derivatives thereof as histone deacetylase inhibitors
ATE425177T1 (de) * 2000-07-17 2009-03-15 Astellas Pharma Inc Reduziertes fk228 und seine verwendung
KR20030031132A (ko) 2000-07-28 2003-04-18 스미또모 세이야꾸 가부시키가이샤 피롤 유도체
US6673587B1 (en) * 2000-08-11 2004-01-06 The Salk Institute For Biological Studies Histone deacetylase, and uses therefor
EP1182263A1 (en) 2000-08-11 2002-02-27 Evotec OAI AG Process for detecting threonine/serine kinase activity
AU2001285042A1 (en) 2000-08-18 2002-03-04 The Governement Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Methods of treating cutaneous and peripheral t-cell lymphoma by a histone deacetylase inhibitor
PE20020354A1 (es) * 2000-09-01 2002-06-12 Novartis Ag Compuestos de hidroxamato como inhibidores de histona-desacetilasa (hda)
WO2002022133A1 (en) 2000-09-12 2002-03-21 Virginia Commonwealth University Promotion of adoptosis in cancer cells by co-administration of cyclin dependent kinase inhibitors and cellular differentiation agents
US6538030B2 (en) * 2000-09-20 2003-03-25 Yih-Lin Chung Treating radiation fibrosis
GB0023983D0 (en) 2000-09-29 2000-11-15 Prolifix Ltd Therapeutic compounds
EP1335898B1 (en) 2000-09-29 2005-11-23 TopoTarget UK Limited Carbamic acid compounds comprising an amide linkage as hdac inhibitors
CA2423744C (en) 2000-09-29 2012-04-03 Prolifix Limited Hydroxamic acid compounds comprising a sulfonamide linkage as hdac inhibitors
AU2002215018A1 (en) 2000-10-13 2002-04-22 Bayer Aktiengesellschaft Human histone deacetylase gene
DE10053474A1 (de) 2000-10-24 2002-05-02 Schering Ag Schwefelhaltige Indirubinderivate, deren Herstellung und Verwendung
US20020103192A1 (en) 2000-10-26 2002-08-01 Curtin Michael L. Inhibitors of histone deacetylase
AU2002212350A1 (en) * 2000-10-31 2002-05-15 Bayer Aktiengesellschaft Regulation of human histone deacetylase
JP2005519848A (ja) 2000-11-02 2005-07-07 スローン−ケッタリング・インスティテュート・フォー・キャンサー・リサーチ Ｈｓｐ９０に結合するための小分子組成物
WO2002055017A2 (en) * 2000-11-21 2002-07-18 Wake Forest University Method of treating autoimmune diseases
DE10061162A1 (de) 2000-11-30 2002-07-11 Schering Ag Aryl-substituierte Indirubinderivate, deren Herstellung und Verwendung
AR035659A1 (es) * 2000-12-07 2004-06-23 Hoffmann La Roche Hidroxiamidas de acido (1-oxo-1,2,3,4-tetrahidro-naftalen-2-il)-alcanoico, proceso para la manufactura de estos compuestos, composiciones farmaceuticas que contienen dichos compuestos y los usos de los mismos
US20040005574A1 (en) * 2002-07-08 2004-01-08 Leonard Guarente SIR2 activity
US6376508B1 (en) * 2000-12-13 2002-04-23 Academia Sinica Treatments for spinal muscular atrophy
US20030154032A1 (en) 2000-12-15 2003-08-14 Pittman Debra D. Methods and compositions for diagnosing and treating rheumatoid arthritis
US20040204373A1 (en) 2000-12-19 2004-10-14 Isis Pharmaceuticals Inc. Antisense modulation of histone deacetylase I expression
US20050171042A1 (en) 2000-12-19 2005-08-04 Monia Brett P. Compositions and their uses directed to binding proteins
US6693132B2 (en) 2000-12-21 2004-02-17 Beacon Laboratories, Inc. Methods for using alkanoyloxymethyl esters
US20040077046A1 (en) * 2000-12-20 2004-04-22 Dalia Cohen Histone deacetylase-related gene and protein
US6720445B2 (en) * 2000-12-21 2004-04-13 Beacon Laboratories, Inc. Acetyloxymethyl esters and methods for using the same
US6562995B1 (en) * 2000-12-21 2003-05-13 Beacon Laboratories, Inc. Delta dicarbonyl compounds and methods for using the same
JP2004516328A (ja) * 2000-12-22 2004-06-03 ヒャン ウー リー アピシジン誘導体、その合成方法、及び該誘導体を含む抗癌剤組成物
AR035513A1 (es) 2000-12-23 2004-06-02 Hoffmann La Roche Derivados de tetrahidropiridina, proceso para prepararlos, composiciones farmaceuticas que los contienen, y uso de dichos compuestos en la preparacion de medicamentos
CA2434269A1 (en) 2001-01-10 2002-07-18 The Government Of The United States Of America Histone deacetylase inhibitors in diagnosis and treatment of thyroid neoplasms
WO2002069947A2 (en) 2001-01-12 2002-09-12 Methylgene, Inc. Antisense oligonucleotides and trichostatin analogue histone deacetylase-4 inhibitors against cancer
US20030152557A1 (en) 2001-01-12 2003-08-14 Besterman Jeffrey M. Methods for inhibiting histone deacetylase-4
US20030148970A1 (en) 2001-01-12 2003-08-07 Besterman Jeffrey M. Methods for specifically inhibiting histone deacetylase-4
US6756200B2 (en) * 2001-01-26 2004-06-29 The Johns Hopkins University School Of Medicine Aberrantly methylated genes as markers of breast malignancy
AR035417A1 (es) 2001-01-27 2004-05-26 Hoffmann La Roche Derivados triciclicos de lactama y sultama, procesos para su elaboracion, medicamentos que los contienen, y el uso de dichos compuestos en la preparacion de medicamentos
WO2002060430A1 (en) 2001-02-01 2002-08-08 Cornell Research Foundation, Inc. Use of retinoids plus histone deacetylase inhibitors to inhibit the growth of solid tumors
US20040091967A1 (en) * 2001-02-05 2004-05-13 Kohler Ranier H Regulation of human histone acetyltranseferase
US20020177594A1 (en) 2001-03-14 2002-11-28 Curtin Michael L. Inhibitors of histone deacetylase
US8026280B2 (en) 2001-03-27 2011-09-27 Errant Gene Therapeutics, Llc Histone deacetylase inhibitors
WO2002076941A2 (en) 2001-03-27 2002-10-03 Circagen Pharmaceutical Histone deacetylase inhibitors
US7312247B2 (en) 2001-03-27 2007-12-25 Errant Gene Therapeutics, Llc Histone deacetylase inhibitors
US6495719B2 (en) * 2001-03-27 2002-12-17 Circagen Pharmaceutical Histone deacetylase inhibitors
DE60113645T2 (de) 2001-04-10 2006-07-06 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Verwendung von Histonedeacetylasehemmern zur Behandlung von Papillomaviren assoziierte Krankheiten
AR035455A1 (es) 2001-04-23 2004-05-26 Hoffmann La Roche Derivados triciclicos de alquilhidroxamato , procesos para su elaboracion, composiciones farmaceuticas que los contienen, y el uso de dichos compuestos en la preparacion de medicamentos
US6905669B2 (en) 2001-04-24 2005-06-14 Supergen, Inc. Compositions and methods for reestablishing gene transcription through inhibition of DNA methylation and histone deacetylase
ES2310213T3 (es) 2001-05-02 2009-01-01 The Regents Of The University Of California Procedimiento para tratar trastornos neurodegenerativos, psiquiatricos y otros trastornos con inhibidores de desacetilasa.
WO2002089782A2 (en) 2001-05-09 2002-11-14 President And Fellows Of Harvard College Dioxanes and uses thereof
US7244853B2 (en) * 2001-05-09 2007-07-17 President And Fellows Of Harvard College Dioxanes and uses thereof
EP1409661A4 (en) 2001-06-14 2006-02-01 Sloan Kettering Inst Cancer HDAC9 POLYPEPTIDES, POLYNUCLEOTIDES AND USES THEREOF
EP1532244A4 (en) 2001-06-14 2005-12-14 Bristol Myers Squibb Co NEW HISTONIC HUMAN DEACETYLASES
US7241743B2 (en) 2001-06-15 2007-07-10 The Trustees Of Columbia University In The City Of New York Sir2α-based therapeutic and prophylactic methods
US6784173B2 (en) 2001-06-15 2004-08-31 Hoffmann-La Roche Inc. Aromatic dicarboxylic acid derivatives
US7488587B2 (en) 2001-06-19 2009-02-10 The J. David Gladstone Institutes Histone deacetylase and methods of use thereof
CA2451654A1 (en) 2001-06-22 2003-01-03 Ceres, Inc. Chimeric histone acetyltransferase polypeptides
EP1411975A4 (en) 2001-07-03 2005-04-27 Univ Virginia METHYLATION OF HISTON H4 AT ARGININE 3
AU2002333315A1 (en) 2001-08-03 2003-02-24 Novartis Ag Human histone deacetylase-related gene and protein hdac10
US20040266718A1 (en) 2001-08-06 2004-12-30 Zuomei Li Inhibition of specific histone deacetylase isoforms
ITMI20011733A1 (it) 2001-08-07 2003-02-07 Italfarmaco Spa Derivati dell'acido idrossamico inibitori degli enzimi istone deacetilasi, quali nuovi farmaci antiinfiammatori inibenti la sintesi di citoc
AR034897A1 (es) 2001-08-07 2004-03-24 Hoffmann La Roche Derivados n-monoacilados de o-fenilendiaminas, sus analogos heterociclicos de seis miembros y su uso como agentes farmaceuticos
HU229521B1 (hu) 2001-08-21 2014-01-28 Astellas Pharma Inc A hiszton-dezacetiláz inhibitor gyógyászati alkalmazása, és eljárás tumorellenes hatásának kiértékelésére
US20040259772A1 (en) 2001-08-24 2004-12-23 Antonio Fojo Use of a histone deacetylase inhibitor to increase the entry of an adenoviral agent into a cell
EP1291015A1 (en) 2001-09-10 2003-03-12 Lunamed AG Dosage forms having prolonged active ingredient release
US7868204B2 (en) 2001-09-14 2011-01-11 Methylgene Inc. Inhibitors of histone deacetylase
EP1429765A2 (en) * 2001-09-14 2004-06-23 Methylgene, Inc. Inhibitors of histone deacetylase
US6897220B2 (en) 2001-09-14 2005-05-24 Methylgene, Inc. Inhibitors of histone deacetylase
EP1293205A1 (en) * 2001-09-18 2003-03-19 G2M Cancer Drugs AG Valproic acid and derivatives thereof for the combination therapy of human cancers, for the treatment of tumour metastasis and minimal residual disease
DE10148618B4 (de) 2001-09-25 2007-05-03 Schering Ag Substituierte N-(1,4,5,6-Tetrahydro-cyclopentapyrazol-3-yl)-Derivate, deren Herstellung und Verwendung als Arzneimittel
US6706686B2 (en) 2001-09-27 2004-03-16 The Regents Of The University Of Colorado Inhibition of histone deacetylase as a treatment for cardiac hypertrophy
GB0123664D0 (en) 2001-10-02 2001-11-21 Inst Of Cancer Res The Histone deacetylase 9
EP1443928B1 (en) * 2001-10-16 2011-07-27 Sloan-Kettering Institute For Cancer Research Treatment of neurodegenerative diseases and cancer of the brain
WO2003033678A2 (en) 2001-10-18 2003-04-24 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Methods of using deacetylase inhibitors to promote cell differentiation and regeneration
CA2461373A1 (en) 2001-11-06 2003-05-15 Novartis Ag Cyclooxygenase-2 inhibitor/histone deacetylase inhibitor combination
CN1310937C (zh) 2001-11-21 2007-04-18 犹太大学阿尔伯特爱因斯坦医学院 Sir2产物及活性
WO2003046207A2 (en) 2001-11-27 2003-06-05 Fred Hutchinson Cancer Research Center Methods for inhibiting deacetylase activity
EP1456664A1 (en) 2001-12-07 2004-09-15 Novartis AG Use of alpha-tubulin acetylation levels as a biomarker for protein deacetylase inhibitors
AU2002351898A1 (en) 2001-12-21 2003-07-09 Universite Libre De Bruxelles Method for obtaining the elimination of integrated and functional viruses from infected mammal cells
CA2471957A1 (en) 2001-12-28 2003-07-17 Fujisawa Pharmaceutical Co., Ltd. Cyclic tetrapeptide compound and use thereof
ITRM20020016A1 (it) 2002-01-15 2003-07-15 Sigma Tau Ind Farmaceuti Derivati di acidi fenil(alchil)carbossilici e derivati fenilalchileterociclici dionici, loro uso come medicamenti ad attivita' ipoglicemizza
EP1474531A4 (en) 2002-01-25 2006-06-14 Univ Texas ELECTROPHORESET TEST FOR THE PREDICT OF CANCER RISK AND THE EFFECTIVENESS AND TOXICITY OF CANCER THERAPY
TWI329105B (en) 2002-02-01 2010-08-21 Rigel Pharmaceuticals Inc 2,4-pyrimidinediamine compounds and their uses
JP2005517007A (ja) 2002-02-07 2005-06-09 アクシス・ファーマスーティカルズ ヒストンデアセチラーゼ阻害剤としての新規二環式ヒドロキサメート
AU2003214055A1 (en) 2002-02-08 2003-09-02 Novartis Ag Method for screening for compounds having hdac inhibitory activity
US20030155067A1 (en) 2002-02-15 2003-08-21 John Syron Method and article for masking portions of a vehicle by adherent appliques
JP2005525345A (ja) 2002-02-15 2005-08-25 スローン−ケッタリング・インスティテュート・フォー・キャンサー・リサーチ Ｔｒｘ媒介性疾患を処置する方法
CN1646558B (zh) 2002-02-20 2010-05-12 国立大学法人九州工业大学 组蛋白脱乙酰酶抑制剂
US7456219B2 (en) 2002-03-04 2008-11-25 Merck Hdac Research, Llc Polymorphs of suberoylanilide hydroxamic acid
WO2003075839A2 (en) 2002-03-04 2003-09-18 Aton Pharma, Inc. Methods of inducing terminal differentiation
US20040132825A1 (en) 2002-03-04 2004-07-08 Bacopoulos Nicholas G. Methods of treating cancer with HDAC inhibitors
US7148257B2 (en) * 2002-03-04 2006-12-12 Merck Hdac Research, Llc Methods of treating mesothelioma with suberoylanilide hydroxamic acid
IL163732A0 (en) * 2002-03-07 2005-12-18 Univ Johns Hopkins Genomic screen for epigenetically silenced tumor suppressor genes
EP1497462A4 (en) 2002-03-07 2007-11-07 Univ Johns Hopkins Med GENOMIC SCREEN ON EPIGENETIC MUTED CANCER ASSOCIATED GENES
DE60326436D1 (en) 2002-03-13 2009-04-16 Janssen Pharmaceutica Nv Aminoderivate als histone-deacetylase-inhibitoren
MXPA04008796A (es) 2002-03-13 2004-11-26 Janssen Pharmaceutica Nv Derivados de carbonilamino como novedosos inhibidores de desacetilasa de histona.
KR20040093692A (ko) 2002-03-13 2004-11-08 얀센 파마슈티카 엔.브이. 히스톤 디아세틸라제의 신규한 저해제로서의 피페라지닐-,피페리디닐- 및 모르폴리닐-유도체
ES2306859T3 (es) 2002-03-13 2008-11-16 Janssen Pharmaceutica Nv Derivados de sulfonil como nuevos inhibidores de histona deacetilasa.
OA12793A (en) 2002-03-13 2006-07-10 Janssen Pharmaceutica Nv Sulfonylamino-derivatives as novel inhibitors of histone deacetylase.
WO2003080864A1 (fr) 2002-03-26 2003-10-02 Exhonit Therapeutics Sa Histone deacetylase: nouvelle cible moleculaire de la neurotoxicite
US20040077591A1 (en) * 2002-03-28 2004-04-22 The Brigham And Women's Hospital, Inc. Histone deacetylase inhibitors for the treatment of multiple sclerosis, amyotrophic lateral sclerosis and Alzheimer's Disease
US6841565B1 (en) * 2002-03-29 2005-01-11 The Ohio State University Treatment of patients with chronic lymphocytic leukemia
CA2479906C (en) 2002-04-03 2011-02-08 Topotarget Uk Limited Carbamic acid compounds comprising a piperazine linkage as hdac inhibitors
TWI319387B (en) 2002-04-05 2010-01-11 Astrazeneca Ab Benzamide derivatives
MXPA04009761A (es) 2002-04-05 2005-05-27 Fujisawa Pharmaceutical Co Dipsipeptido para terapia de cancer renal.
WO2003087066A1 (en) 2002-04-11 2003-10-23 Sk Chemicals, Co., Ltd. α,β-UNSATURATED HYDROXAMIC ACID DERIVATIVES AND THEIR USE AS HISTONE DEACETYLASE INHIBITORS
MY134200A (en) 2002-04-12 2007-11-30 Kowa Co Method for treating cancer
CN100566711C (zh) * 2002-04-15 2009-12-09 斯隆-凯特林癌症研究院 治疗癌症的化合物及其用途
US6620838B1 (en) 2002-04-19 2003-09-16 Signal Pharmaceuticals, Inc. Benzopyrazone compounds, compositions thereof, and methods of treatment therewith
US20030206946A1 (en) 2002-04-26 2003-11-06 Yih-Lin Chung Methods for therapy of connective tissue disease
US6809118B2 (en) 2002-07-25 2004-10-26 Yih-Lin Chung Methods for therapy of radiation cutaneous syndrome
US20040018522A1 (en) * 2002-05-09 2004-01-29 Brigham And Women's Hospital, Inc. Identification of dysregulated genes in patients with multiple sclerosis
EP1362914A3 (en) 2002-05-15 2004-05-06 Schering AG Histone deacetylase inhibitor and use thereof
US7351542B2 (en) * 2002-05-20 2008-04-01 The Regents Of The University Of California Methods of modulating tubulin deacetylase activity
WO2003099272A1 (en) 2002-05-22 2003-12-04 Errant Gene Therapeutics, Llc Histone deacetylase inhibitors based on alpha-ketoepoxide compounds
AU2003247390A1 (en) * 2002-05-22 2003-12-12 Errant Gene Therapeutics, Llc. Histone deacetylase inhibitors based on alphachalcogenmethylcarbonyl compounds
CA2486385C (en) 2002-05-22 2013-12-10 Errant Gene Therapeutics, Llc Histone deacetylase inhibitors based on trihalomethylcarbonyl compounds
CA2484013C (en) 2002-05-23 2011-09-20 The Regents Of The University Of California Methods of modulating mitochondrial nad-dependent deacetylase
US20030224473A1 (en) 2002-05-23 2003-12-04 Mccafferty Dewey G. Methods for screening for histone deacetylase activity and for identifying histone deacetylase inhibitors
US20040002447A1 (en) * 2002-06-04 2004-01-01 Regents Of The University Of California Induction of insulin expression
EP2179745A1 (en) 2002-06-10 2010-04-28 Novartis AG Combinations comprising epothilones and pharmaceutical uses thereof
AU2002349786A1 (en) 2002-06-19 2004-01-06 Japan As Represented By The President Of The University Of Tokyo Method for diagnosis of colorectal tumors
US20050084967A1 (en) * 2002-06-28 2005-04-21 Xcyte Therapies, Inc. Compositions and methods for eliminating undesired subpopulations of T cells in patients with immunological defects related to autoimmunity and organ or hematopoietic stem cell transplantation
US20040142993A1 (en) 2002-07-01 2004-07-22 Carlo Battistini Inhibitors of HCV NS5B polymerase
US20040072770A1 (en) * 2002-07-03 2004-04-15 Besterman Jeffrey M. Methods for specifically inhibiting histone deacetylase-7 and 8
GB0215844D0 (en) 2002-07-09 2002-08-14 Novartis Ag Organic compounds
SE0202157D0 (sv) * 2002-07-09 2002-07-09 Biovitrum Ab Methods for identification of compounds modulating insulin resistance
AU2003251942A1 (en) 2002-07-17 2004-02-02 Titan Pharmaceuticals, Inc. Combination of chemotherapeutic drugs for increasing antitumor activity
US20040082565A1 (en) 2002-07-17 2004-04-29 Chemgenex Therapeutics, Inc. Formulations and methods of administration of cephalotaxines including homoharringtonine
DE10233412A1 (de) 2002-07-23 2004-02-12 4Sc Ag Neue Verbindungen als Histondeacetylase-Inhibitoren
US20050176686A1 (en) 2002-07-23 2005-08-11 4Sc Ag Novel compounds as histone deacetylase inhibitors
WO2004009771A2 (en) 2002-07-24 2004-01-29 Advanced Stent Technologies, Inc. Stents capable of controllably releasing histone deacetylase inhibitors
KR101083852B1 (ko) 2002-07-25 2011-11-15 소니 주식회사 유전자 전사 조절제 및 히스톤 탈아세틸화효소 저해 화합물의 스크리닝 방법
PL374970A1 (en) 2002-08-02 2005-11-14 Argenta Discovery Limited Substituted thienyl-hydroxamic acids as histone deacetylase inhibitors
US20050272647A1 (en) 2002-08-20 2005-12-08 Noboru Yamaji Arthrodial cartilage extracellular matrix degradation inhibitor
US7098186B2 (en) 2002-08-30 2006-08-29 Astellas Pharma Inc Depsipeptide compound
JP2006501267A (ja) 2002-09-13 2006-01-12 バージニア コモンウェルス ユニバーシティー 白血病の処置のためのａ）Ｎ−｛５−［４−（４−メチル−ピペラジノ−メチル）−ベンゾイルアミド］−２−メチルフェニル｝−４−（３−ピリジル）−２−ピリミジン−アミンおよびｂ）ヒストンデアセチラーゼインヒビターの組合せ剤
EP1400806A1 (en) 2002-09-18 2004-03-24 G2M Cancer Drugs AG The use of molecular markers for the preclinical and clinical profiling of inhibitors of enzymes having histone deacetylase activity
EP1545536A4 (en) 2002-09-19 2009-11-11 Univ South Florida PROCESS FOR TREATING LEUKUIA WITH A COMBINATION OF SUBEROYLANILID HYDROMAXINE SURFACE AND IMATINIB MESYLATE
EP1403639A1 (en) 2002-09-30 2004-03-31 G2M Cancer Drugs AG Antibody tools for the diagnostic use in the medical therapy with inhibitors of histone deacetylases
US20040077084A1 (en) * 2002-10-17 2004-04-22 Isis Pharmaceuticals Inc. Antisense modulation of histone deacetylase 4 expression
US20040077083A1 (en) * 2002-10-17 2004-04-22 Isis Pharmaceuticals Inc. Antisense modulation of histone deacetylase 4 expression
JP2006503082A (ja) 2002-10-17 2006-01-26 メシルジーン、インコーポレイテッド ヒストンデアセチラーゼの阻害剤
CN1711086A (zh) 2002-11-12 2005-12-21 爱尔康公司 用于治疗眼的退化性疾病的组蛋白脱乙酰酶抑制剂
JP2006512318A (ja) 2002-11-12 2006-04-13 アルコン，インコーポレイテッド 眼の血管新生もしくは水腫状の疾患および障害を処置するためのヒストンデアセチラーゼインヒビター
AU2003295444A1 (en) 2002-11-15 2004-06-15 The Board Of Trustees Of The University Of Illinois Methods for in vitro expansion of hematopoietic stem cells
GB0226855D0 (en) 2002-11-18 2002-12-24 Queen Mary & Westfield College Histone deacetylase inhibitors
WO2004046104A2 (en) 2002-11-20 2004-06-03 Errant Gene Therapeutics, Llc Treatment of lung cells with histone deacetylase inhibitors
AU2003296310A1 (en) 2002-12-06 2004-06-30 University Of South Florida Histone deacetylase inhibitor enhancement of trail-induced apoptosis
EP1590318A2 (en) 2002-12-12 2005-11-02 Jawaharlal Nehru Centre For Advanced Scientific Research Modulators (inhibitors/activators) of histone acetyltransferases
US7098241B2 (en) 2002-12-16 2006-08-29 Hoffmann-La Roche Inc. Thiophene hydroxamic acid derivatives
ITMI20022745A1 (it) 2002-12-23 2004-06-24 Coimex Scrl United Companies Esteri misti dell'acido ialuronico ad attivita' citostatica e prodifferenziante e procedimento per la loro produzione.
US20040197888A1 (en) 2002-12-31 2004-10-07 Armour Christopher D. Alternatively spliced isoforms of histone deacetylase 3 (HDAC3)
ITMI20030025A1 (it) 2003-01-10 2004-07-11 Italfarmaco Spa Derivati dell'acido idrossammico ad attivita' antinfiammatoria.
TW200418806A (en) 2003-01-13 2004-10-01 Fujisawa Pharmaceutical Co HDAC inhibitor
US20050222013A1 (en) 2003-01-16 2005-10-06 Georgetown University Methods for the use of inhibitors of histone deacetylase as synergistic agents in cancer therapy
US7465719B2 (en) 2003-01-17 2008-12-16 Topotarget Uk Limited Carbamic acid compounds comprising an ester or ketone linkage as HDAC inhibitors
WO2004067480A2 (en) 2003-01-25 2004-08-12 Oxford Glycosciences (Uk) Ltd Substituted phenylurea derivatives as hdac inhibitors
US7572922B2 (en) 2003-01-27 2009-08-11 Merck & Co., Inc. Substituted pyrazoles, compositions containing such compounds and methods of use
US7208491B2 (en) 2003-02-07 2007-04-24 Hoffmann-La Roche Inc. N-monoacylated o-phenylenediamines
WO2004072265A2 (en) 2003-02-11 2004-08-26 Wyeth Methods for monitoring drug activities in vivo
AU2003900587A0 (en) 2003-02-11 2003-02-27 Fujisawa Pharmaceutical Co., Ltd. Hdac inhibitor
AU2003900608A0 (en) 2003-02-11 2003-02-27 Fujisawa Pharmaceutical Co., Ltd. Hdac inhibitor
US20040241856A1 (en) 2003-02-12 2004-12-02 Irm Llc, A Delaware Limited Liability Company Methods and compositions for modulating stem cells
WO2004071464A2 (en) 2003-02-12 2004-08-26 Johns Hopkins University School Of Medicine Diagnostic application of differentially-expressed genes in lympho-hematopoietic stem cells
US7244751B2 (en) 2003-02-14 2007-07-17 Shenzhen Chipscreen Biosciences Ltd. Histone deacetylase inhibitors of novel benzamide derivatives with potent differentiation and anti-proliferation activity
US20080233562A1 (en) 2003-02-19 2008-09-25 Astellas Pharma Inc. Method of Estimating Antitumor Effect of Histone Deacetylase Inhibitor
US7652036B2 (en) 2003-02-25 2010-01-26 Topotarget Uk Limited Carbamic acid compounds comprising a bicyclic heteroaryl group as HDAC inhibitors
CA2518318A1 (en) 2003-03-17 2004-09-30 Takeda San Diego, Inc. Histone deacetylase inhibitors
CN1839121A (zh) 2003-04-01 2006-09-27 斯隆-凯特林癌症研究所 异羟肟酸化合物及其使用方法
TW200424187A (en) 2003-04-04 2004-11-16 Hoffmann La Roche New oxime derivatives and their use as pharmaceutically active agents
SI1611088T1 (sl) 2003-04-07 2009-12-31 Pharmacyclics Inc Hidroksamati kot terapevtska sredstva
AU2004232973A1 (en) 2003-04-18 2004-11-04 Memory Pharmaceuticals Corporation Pyrazole derivatives as phosphodiesterase 4 inhibitors
US20040213826A1 (en) 2003-04-28 2004-10-28 Marx Steven O. Medical devices and methods for inhibiting proliferation of smooth muscle cells
CN1791396A (zh) 2003-05-21 2006-06-21 诺瓦提斯公司 组蛋白脱乙酰基酶抑制剂与化疗剂的组合
EP1631268A2 (en) 2003-05-21 2006-03-08 Board Of Regents The University Of Texas System Inhibition of protein kinase c-mu (pkd) as a treatment for cardiac hypertrophy and heart failure
PE20050206A1 (es) 2003-05-26 2005-03-26 Schering Ag Composicion farmaceutica que contiene un inhibidor de histona deacetilasa
US20050020557A1 (en) 2003-05-30 2005-01-27 Kosan Biosciences, Inc. Method for treating diseases using HSP90-inhibiting agents in combination with enzyme inhibitors
AU2004247136A1 (en) 2003-06-10 2004-12-23 Kalypsys, Inc. Carbonyl compounds as inhibitors of histone deacetylase for the treatment of disease
US7271195B2 (en) * 2003-06-10 2007-09-18 Kalypsys, Inc. Carbonyl compounds as inhibitors of histone deacetylase for the treatment of disease
US20060235012A1 (en) 2003-06-16 2006-10-19 Chroma Therapeutics Limited Carboline and betacarboline derivatives for use as hdac enzyme inhibitors
EP1491188A1 (en) 2003-06-25 2004-12-29 G2M Cancer Drugs AG Topical use of valproic acid for the prevention or treatment of skin disorders
DK2238982T3 (da) 2003-06-27 2013-01-28 Astellas Pharma Inc Terapeutisk middel til blødt væv-sarcom
CA2529510A1 (en) 2003-07-01 2005-01-13 President And Fellows Of Harvard College Compositions for manipulating the lifespan and stress response of cells and organisms
EP1648459A1 (en) 2003-07-02 2006-04-26 Albert Einstein College Of Medicine Of Yeshiva University Sir2 regulation
US7842835B2 (en) 2003-07-07 2010-11-30 Georgetown University Histone deacetylase inhibitors and methods of use thereof
EP1644323B1 (en) 2003-07-07 2015-03-18 Georgetown University Histone deacetylase inhibitors and methods of use thereof
WO2005004861A1 (en) 2003-07-15 2005-01-20 Korea Research Institute Of Bioscience And Biotechnology A use of novel 2-oxo-heterocyclic compounds and the pharmaceutical compositions comprising the same
GB0316889D0 (en) 2003-07-18 2003-08-20 Univ London Pharmaceutical agents
US20050037992A1 (en) 2003-07-22 2005-02-17 John Lyons Composition and method for treating neurological disorders
WO2005011598A2 (en) 2003-07-31 2005-02-10 University Of South Florida Leukemia treatment method and composition
WO2005014588A1 (en) 2003-08-01 2005-02-17 Argenta Discovery Limited Substituted thienyl-hydroxamic acids having histone deacetylase activity
US20050032794A1 (en) * 2003-08-05 2005-02-10 Padia Janak K. Diamine derivatives of quinone and uses thereof
US20060270730A1 (en) 2003-08-07 2006-11-30 Andreas Katopodis Histone deacetylase inhibitors as immunosuppressants
BRPI0413439A (pt) 2003-08-08 2006-10-17 Novartis Ag combinações compreendendo estaurosporinas
DE602004004665T2 (de) 2003-08-20 2008-01-03 Pharmacyclics, Inc., Sunnyvale Acetylenderivate als inhibitoren von histondeacetylase
KR100924737B1 (ko) 2003-08-26 2009-11-04 슬로안-케테링인스티튜트퍼캔서리서치 Ｈｄａｃ 억제제를 이용한 암의 치료 방법
CA2535889A1 (en) 2003-08-29 2005-03-17 Aton Pharma, Inc. Combination methods of treating cancer
US20050059682A1 (en) * 2003-09-12 2005-03-17 Supergen, Inc., A Delaware Corporation Compositions and methods for treatment of cancer
WO2005028620A2 (en) 2003-09-16 2005-03-31 The Rockefeller University Histone modifications as binary switches controlling gene expression
SI1668014T1 (sl) 2003-09-17 2009-06-30 Janssen Pharmaceutica Nv Kondenzirane heterociklične spojine kot modulatorji serotoninskih receptorjev
JP2007505860A (ja) 2003-09-18 2007-03-15 ノバルティス　アクチエンゲゼルシャフト ヒストンデアセチラーゼ阻害剤と細胞死受容体リガンドの組み合わせ
PT1673349E (pt) 2003-09-22 2010-09-28 S Bio Pte Ltd Derivados benzimidazole: preparação e aplicações farmacêuticas
KR101153335B1 (ko) 2003-09-24 2012-07-05 메틸진 인코포레이티드 히스톤 데아세틸라제의 억제제
PL1670514T3 (pl) * 2003-09-25 2010-11-30 Astellas Pharma Inc Środek przeciwnowotworowy zawierający inhibitor deacetylazy histonowej i inhibitor topoizomerazy II
WO2005034880A2 (en) 2003-10-09 2005-04-21 Aton Pharma, Inc. Thiophene and benzothiophene hydroxamic acid derivatives
US20050124625A1 (en) 2003-10-21 2005-06-09 Salvati Mark E. Piperazine derivatives and their use as modulators of nuclear hormone receptor function
US20070167499A1 (en) 2003-10-27 2007-07-19 A*Bio Pte Ltd. Biaryl linked hydroxamates: preparation and pharmaceutical applications
CA2543570A1 (en) 2003-10-27 2005-05-06 S*Bio Pte Ltd Acylurea connected and sulfonylurea connected hydroxamates
IN2003CH00929A (https=) 2003-11-13 2008-10-06
CN1905881A (zh) 2003-11-26 2007-01-31 阿托恩药品公司 二胺和亚氨二醋酸异羟肟酸衍生物
WO2005053609A2 (en) 2003-11-26 2005-06-16 Guilford Pharmaceuticals Inc. Methods of nad+-dependent deacetylase inhibitors
US20080004290A1 (en) 2003-11-28 2008-01-03 The University Of Queensland Anti-Cancer Agents
DK1696898T3 (en) 2003-12-02 2016-02-22 Univ Ohio State Res Found ZN2 + -CHELATING DESIGN-BASED SHORT-CHAIN FAT ACIDS AS AN UNKNOWN CLASS OF HISTONDEACETYLASE INHIBITORS
WO2005058298A2 (en) 2003-12-10 2005-06-30 Wisconsin Alumni Research Foundation Fk228 analogs and their use as hdac-inhibitors
EP1541549A1 (en) 2003-12-12 2005-06-15 Exonhit Therapeutics S.A. Tricyclic hydroxamate and benzaminde derivatives, compositions and methods
US8652502B2 (en) 2003-12-19 2014-02-18 Cordis Corporation Local vascular delivery of trichostatin A alone or in combination with sirolimus to prevent restenosis following vascular injury
US20050137234A1 (en) 2003-12-19 2005-06-23 Syrrx, Inc. Histone deacetylase inhibitors
WO2005065681A1 (en) 2003-12-19 2005-07-21 Takeda San Diego, Inc. N- hydroxy-3-(3-(1h-imidazol-2-yl)-phenyl)-acrylamide derivatives and related compounds as histone deacetylase (hdac) inhibitors for the treatment of cancer
EP1708689A2 (en) 2003-12-29 2006-10-11 The President and Fellows of Harvard College Compositions for treating or preventing obesity and insulin resistance disorders
CA2553468A1 (en) 2004-01-21 2005-08-04 Istituto Di Ricerche Di Biologia Molecolare P. Angeletti Spa Inhibitors of mammalian hdac 11 useful for treating hdac 11 mediated disorders
AU2005225471B2 (en) 2004-03-26 2011-05-12 Methylgene Inc. Inhibitors of histone deacetylase
JP2008524246A (ja) 2004-12-16 2008-07-10 タケダ サン ディエゴ インコーポレイテッド ヒストンデアセチラーゼ阻害剤
US7642253B2 (en) 2005-05-11 2010-01-05 Takeda San Diego, Inc. Histone deacetylase inhibitors
EA200800321A1 (ru) 2005-07-14 2008-06-30 Такеда Сан Диего, Инк. Ингибиторы гистондеацетилазы

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH10152462A (ja) * 1996-09-30 1998-06-09 Mitsui Chem Inc 分化誘導剤
WO2003092686A1 (en) * 2002-04-27 2003-11-13 Astrazeneca Ab Inhibitors of histone deacetylase
WO2004052838A1 (en) * 2002-12-10 2004-06-24 F. Hoffmann-La Roche Ag Arylene-carboxylic acid (2-amino-phenyl)-amide derivatives as pharmaceutical agents
WO2004058234A2 (en) * 2002-12-27 2004-07-15 Schering Aktiengesellschaft Pharmaceutical combinations of phthalazine vegf inhibitors and benzamide hdac inhibitors
WO2004069803A2 (en) * 2003-02-06 2004-08-19 F. Hoffmann-La Roche Ag Mono-acylated o-phenylendiamines derivatives and their use against cancer

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5484069B2 (ja) * 2007-12-19 2014-05-07 大日本住友製薬株式会社 二環性へテロ環誘導体

Also Published As

Publication number Publication date
WO2006066133A2 (en) 2006-06-22
WO2006066133A3 (en) 2006-08-31
EP1824831A2 (en) 2007-08-29
US7642275B2 (en) 2010-01-05
US20060205941A1 (en) 2006-09-14

Similar Documents

Publication Publication Date Title
JP2008524246A (ja) ヒストンデアセチラーゼ阻害剤
US7732475B2 (en) Histone deacetylase inhibitors
JP2009525955A (ja) ヒストンデアセチラーゼ阻害剤
US7399884B2 (en) Histone deacetylase inhibitors
JP2008540574A (ja) ヒストンデアセチラーゼ阻害剤
JP2006520796A (ja) ヒストンデアセチラーゼインヒビター
EP2227469B9 (en) Mapk/erk kinase inhibitors
US8063066B2 (en) MAPK/ERK kinase inhibitors
US20050159470A1 (en) Histone deacetylase inhibitors
JP2008501714A (ja) ジペプチジルペプチダーゼインヒビター
JP2009515997A (ja) グルコキナーゼ活性剤
JP2008506708A (ja) ジペプチジルぺプチダーゼ阻害剤
JPWO2019078246A1 (ja) Ｉｄｏ／ｔｄｏ阻害剤
HK1122561A (en) Histone deacetylase inhibitors

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20081212

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20081212

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20120124

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20120626